Cargando…
RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
Background: We have previously shown that overexpression of RANK-c in ER-negative breast cancer cell lines attenuates aggressive properties of cancer cells, partially through a RANK-c/EGFR interaction. EGFR inhibition through TKIs in breast cancer has been tested in triple-negative disease settings...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619104/ https://www.ncbi.nlm.nih.gov/pubmed/34828291 http://dx.doi.org/10.3390/genes12111686 |
_version_ | 1784604909180551168 |
---|---|
author | Sirinian, Chaido Papanastasiou, Anastasios D. Degn, Soren E. Frantzi, Theodora Aronis, Christos Chaniotis, Dimitrios Makatsoris, Thomas Koutras, Angelos Kalofonos, Haralabos P. |
author_facet | Sirinian, Chaido Papanastasiou, Anastasios D. Degn, Soren E. Frantzi, Theodora Aronis, Christos Chaniotis, Dimitrios Makatsoris, Thomas Koutras, Angelos Kalofonos, Haralabos P. |
author_sort | Sirinian, Chaido |
collection | PubMed |
description | Background: We have previously shown that overexpression of RANK-c in ER-negative breast cancer cell lines attenuates aggressive properties of cancer cells, partially through a RANK-c/EGFR interaction. EGFR inhibition through TKIs in breast cancer has been tested in triple-negative disease settings with limited clinical benefit for patients. Here we test if expression of RANK-c in ER-negative breast cancer cells in conjunction with treatment with TK inhibitors (erlotinib or gefitinib) can affect survival and colony-forming capacity of cancer cells. Methods: Stably expressing MDA-MB-231-RANK-c and SKBR3-RANK-c cells were employed to test proliferation and colony formation in the presence of TKIs. In addition, Western blot analysis was performed to dissect EGFR related signaling cascades upon TK inhibition in the presence of RANK-c. Results: Interestingly the two RANK-c expressing, ER-negative cells lines presented with a distinct phenotype concerning TKI sensitivity upon treatment. MDA-MB-231-RANK-c cells had a higher sensitivity upon gefitinib treatment, while erlotinib decreased the proliferation rate of SKBR3-RANK-c cells. Further, colony formation assays for MDA-MB-231-RANK-c cells showed a decrease in the number and size of colonies developed in the presence of erlotinib. In addition, RANK-c seems to alter signaling through EGFR after TKI treatment in a cell type-specific manner. Conclusions: Our results indicate that ER-negative breast cancer cells that express RANK-c alter their sensitivity profile against tyrosine kinase inhibitors (erlotinib and gefitinib) in a cell type-specific and culture substrate-dependent manner. |
format | Online Article Text |
id | pubmed-8619104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86191042021-11-27 RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs) Sirinian, Chaido Papanastasiou, Anastasios D. Degn, Soren E. Frantzi, Theodora Aronis, Christos Chaniotis, Dimitrios Makatsoris, Thomas Koutras, Angelos Kalofonos, Haralabos P. Genes (Basel) Communication Background: We have previously shown that overexpression of RANK-c in ER-negative breast cancer cell lines attenuates aggressive properties of cancer cells, partially through a RANK-c/EGFR interaction. EGFR inhibition through TKIs in breast cancer has been tested in triple-negative disease settings with limited clinical benefit for patients. Here we test if expression of RANK-c in ER-negative breast cancer cells in conjunction with treatment with TK inhibitors (erlotinib or gefitinib) can affect survival and colony-forming capacity of cancer cells. Methods: Stably expressing MDA-MB-231-RANK-c and SKBR3-RANK-c cells were employed to test proliferation and colony formation in the presence of TKIs. In addition, Western blot analysis was performed to dissect EGFR related signaling cascades upon TK inhibition in the presence of RANK-c. Results: Interestingly the two RANK-c expressing, ER-negative cells lines presented with a distinct phenotype concerning TKI sensitivity upon treatment. MDA-MB-231-RANK-c cells had a higher sensitivity upon gefitinib treatment, while erlotinib decreased the proliferation rate of SKBR3-RANK-c cells. Further, colony formation assays for MDA-MB-231-RANK-c cells showed a decrease in the number and size of colonies developed in the presence of erlotinib. In addition, RANK-c seems to alter signaling through EGFR after TKI treatment in a cell type-specific manner. Conclusions: Our results indicate that ER-negative breast cancer cells that express RANK-c alter their sensitivity profile against tyrosine kinase inhibitors (erlotinib and gefitinib) in a cell type-specific and culture substrate-dependent manner. MDPI 2021-10-23 /pmc/articles/PMC8619104/ /pubmed/34828291 http://dx.doi.org/10.3390/genes12111686 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Sirinian, Chaido Papanastasiou, Anastasios D. Degn, Soren E. Frantzi, Theodora Aronis, Christos Chaniotis, Dimitrios Makatsoris, Thomas Koutras, Angelos Kalofonos, Haralabos P. RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs) |
title | RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs) |
title_full | RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs) |
title_fullStr | RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs) |
title_full_unstemmed | RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs) |
title_short | RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs) |
title_sort | rank-c expression sensitizes er-negative, egfr-positive breast cancer cells to egfr-tyrosine kinase inhibitors (tkis) |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619104/ https://www.ncbi.nlm.nih.gov/pubmed/34828291 http://dx.doi.org/10.3390/genes12111686 |
work_keys_str_mv | AT sirinianchaido rankcexpressionsensitizesernegativeegfrpositivebreastcancercellstoegfrtyrosinekinaseinhibitorstkis AT papanastasiouanastasiosd rankcexpressionsensitizesernegativeegfrpositivebreastcancercellstoegfrtyrosinekinaseinhibitorstkis AT degnsorene rankcexpressionsensitizesernegativeegfrpositivebreastcancercellstoegfrtyrosinekinaseinhibitorstkis AT frantzitheodora rankcexpressionsensitizesernegativeegfrpositivebreastcancercellstoegfrtyrosinekinaseinhibitorstkis AT aronischristos rankcexpressionsensitizesernegativeegfrpositivebreastcancercellstoegfrtyrosinekinaseinhibitorstkis AT chaniotisdimitrios rankcexpressionsensitizesernegativeegfrpositivebreastcancercellstoegfrtyrosinekinaseinhibitorstkis AT makatsoristhomas rankcexpressionsensitizesernegativeegfrpositivebreastcancercellstoegfrtyrosinekinaseinhibitorstkis AT koutrasangelos rankcexpressionsensitizesernegativeegfrpositivebreastcancercellstoegfrtyrosinekinaseinhibitorstkis AT kalofonosharalabosp rankcexpressionsensitizesernegativeegfrpositivebreastcancercellstoegfrtyrosinekinaseinhibitorstkis |